These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34152947)

  • 1. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.
    Amirthalingam G; Whitaker H; Brooks T; Brown K; Hoschler K; Linley E; Borrow R; Brown C; Watkins N; Roberts DJ; Solomon D; Gower CM; de Waroux OLP; Andrews NJ; Ramsay ME
    Emerg Infect Dis; 2021 Jul; 27(7):1795-1801. PubMed ID: 34152947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response.
    Otter AD; Bown A; D'Arcangelo S; Bailey D; Semper A; Hewson J; Catton M; Perumal P; Sweed A; McKee DF; Jones J; Harvala H; Lamikanra A; Zambon M; Andrews N; Whitaker H; Linley E; Mentzer AJ; Skelly D; Knight JC; Klenerman P; ; Amirthalingam G; Taylor S; Rowe C; Vipond R; Brooks T
    Microbiol Spectr; 2022 Feb; 10(1):e0228921. PubMed ID: 35196807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
    Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ
    PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil.
    Chaves DG; Takahashi RHC; Campelo F; da Silva Malta MCF; de Oliveira IR; Barbosa-Stancioli EF; Ribeiro MA; Martins ML
    Emerg Infect Dis; 2022 Apr; 28(4):734-742. PubMed ID: 35180375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.
    Cassaniti I; Percivalle E; Sarasini A; Cambiè G; Vecchio Nepita E; Maserati R; Ferrari A; Corcione A; Di Martino R; Bonetti A; Di Napoli A; Ferrari G; Baldanti F
    Clin Microbiol Infect; 2021 Jun; 27(6):914.e1-914.e4. PubMed ID: 33677083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the Diagnostic Performance of Different Principles of SARS-CoV-2 Commercial Antibody Tests in COVID-19 Patients].
    Dinç HÖ; Özdemir YE; Alkan S; Güngördü Dalar Z; Gareayaghi N; Sirekbasan S; Tuyji Tok Y; Kuşkucu MA; Karaali R; Özbey D; Aygün G; Midilli K; Kocazeybek B
    Mikrobiyol Bul; 2021 Apr; 55(2):207-222. PubMed ID: 33882652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays.
    Harley K; Gunsolus IL
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33106364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study.
    Lewin A; De Serres G; Grégoire Y; Perreault J; Drouin M; Fournier MJ; Tremblay T; Beaudoin J; Boivin A; Goyette G; Finzi A; Bazin R; Germain M; Delage G; Renaud C
    Can J Public Health; 2022 Jun; 113(3):385-393. PubMed ID: 35380364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of six commercially available SARS-CoV-2 antibody assays-Choice of assay depends on intended use.
    Nilsson AC; Holm DK; Justesen US; Gorm-Jensen T; Andersen NS; Øvrehus A; Johansen IS; Michelsen J; Sprogøe U; Lillevang ST
    Int J Infect Dis; 2021 Feb; 103():381-388. PubMed ID: 33310021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.
    Fischer B; Knabbe C; Vollmer T
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological Evaluation of Human Antibodies of the Immunoglobulin Class A and G Against SARS-CoV-2 in Serum Collected in Newfoundland and Labrador.
    Needle R; Gilbert L; Zahariadis G; Yu Y; Dalton-Kenny H; Russell RS; Wang P; Donovan C; Hookey S; Jiao L
    Viral Immunol; 2021 Apr; 34(3):182-189. PubMed ID: 33739895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).
    Piron M; Jané M; Ciruela P; Basile L; Martínez A; Puig L; Bes M; Sauleda S
    Blood Transfus; 2022 Sep; 20(5):353-361. PubMed ID: 35175189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy.
    Ferrari M; Di Marco L; Pivetti A; Paduano S; Vecchi C; Bernabucci V; Critelli RM; Lasagni S; De Maria M; Venturelli D; Pecorari M; Boaretto G; Serpini GF; Romagnoli D; Mantovani R; Ceccherelli GB; Villa E
    Emerg Infect Dis; 2023 Jul; 29(7):1479-1481. PubMed ID: 37253276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
    Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for COVID-19: a few points to remember.
    Krátká Z; Luxová Š; Malíčková K; Fürst T; Šimková H
    Cas Lek Cesk; 2020; 159(2):72-77. PubMed ID: 32434339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays.
    Kahre E; Galow L; Unrath M; Haag L; Blankenburg J; Dalpke AH; Lück C; Berner R; Armann JP
    Sci Rep; 2021 Jul; 11(1):14893. PubMed ID: 34290329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.